Industry Insights
-
Outsourced, In-House, Or A Combo: An Agile Recruiting Strategy Fuels Growth In Pharmas And Biotechs
7/28/2025
There are different staffing options for building an agile and scalable team that can quickly react to shifting needs, resources, and funding.
-
5 Best Practices For Improving AI Literacy In A GxP Environment
7/25/2025
ERA Sciences' Ben O'Brien shares five tips to improve pharma and biotech companies' AI literacy when operating in a GxP environment.
-
AI Data Security: The 83% Compliance Gap Facing Pharmaceutical Companies
7/23/2025
A new study reveals a shocking truth: only 17% of pharmaceutical companies — including many CDMOs — have implemented automated controls to prevent sensitive data from leaking through AI tools.
-
All Of Us Need To Be Rooting For The FDA
7/23/2025
In light of FDA leadership changes and operational updates, FDA Matters' Steven Grossman asks us all to slow down and consider why we should be cheering on, not tearing down, the present-day FDA.
-
Here's What Limits AI's Outlook For Replacing Knowledge Workers
7/21/2025
Even after AI developers clean up hallucinations and other short-term issues, a large-scale workforce replacement faces a few intractable obstacles.
-
How Much Knowledge Work Can Biopharma Offload To AI? Answer: Not Much
7/21/2025
In biomanufacturing, knowledge work and manual work are deeply intertwined. One expert suggests replacing entire workflows with artificial intelligence seems unlikely.
-
Tales From The Trenches: Developing Potency Assays Outside Big Pharma
7/18/2025
Lessons learned from developing potency assays to detect activity and variation for cell- and receptor-mediated products — beyond the comforts of a well-heeled company.
-
Is Your Pharma Facility Ready For The Next Public Health Crisis?
7/17/2025
Preventive measures wane as a sense of security resumes. Follow these tips to protect business continuity in the next global health crisis.
-
FDA Leading The Decline Of Animal Testing
7/16/2025
The gold standard practice of conducting animal studies for evaluating toxicity, pharmacodynamics, and immunogenicity is being challenged by innovative alternatives – New Approach Methods (NAMs).
-
A Flexible Mindset For Bridging Between Cell-Based Assay Groups
7/16/2025
Transferring cell-based assays for biologics starts with defining operator and equipment parameters, positive and negative controls, and a sufficient dynamic range.